ACPU
ICPT

Arrowgrass Capital Partners (US)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,000
Closed -$4.23M – 574
2015
Q1 		$4.23M Buy
+15,000
New +$3.25M 0.07% 162

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Carmignac Gestion
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fred Alger Management
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ICPT Position: Q2 2015 in Review

Arrowgrass Capital Partners (US) sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2015, closing a stake of 15,000 shares — an estimated $4.23M sold.

Arrowgrass Capital Partners (US) first reported a position in ICPT in Q1 2015 and held it in 1 quarter. The position peaked at $4.23M in Q1 2015. 191 funds tracked by Wall St. Rank hold ICPT as of Q2 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 15,000 Intercept Pharmaceuticals, Inc. shares in Q2 2015, an estimated $4.23M.
  • Arrowgrass Capital Partners (US) first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s Intercept Pharmaceuticals, Inc. position peaked at $4.23M in Q1 2015.
  • 191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q2 2015, filed 14 Aug 2015.